Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATNM Actinium Pharmaceuticals	$1.74 +1.8%	$1.59	$1.03 ▼ $2.41	$53.35M	-0.53	413,994 shs	122,957 shs
CEMI Chembio Diagnostics	$0.46	$0.43	$0.19 ▼ $1.24	$16.71M	1.85	661,416 shs	351,642 shs
ELYM Eliem Therapeutics	$2.38 +8.7%	$1.48	$2.35 ▼ $11.55	$70.81M	-0.39	486,688 shs	803,871 shs
NBRV Nabriva Therapeutics		$0.00	$1.22 ▼ $8.45	$45.46M	1.53	29,344 shs	1 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATNM Actinium Pharmaceuticals	+1.75%	+2.96%	-6.95%	+6.10%	-17.92%
CEMI Chembio Diagnostics	0.00%	0.00%	0.00%	0.00%	0.00%
ELYM Eliem Therapeutics	-2.67%	+27.33%	+55.32%	+85.59%	-63.98%
NBRV Nabriva Therapeutics	0.00%	0.00%	0.00%	0.00%	+4,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATNM Actinium Pharmaceuticals	3.0107 of 5 stars	3.5	5.0	0.0	0.0	2.8	0.0	0.6
CEMI Chembio Diagnostics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ELYM Eliem Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NBRV Nabriva Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATNM Actinium Pharmaceuticals	3.00	Buy	$4.50	158.62% Upside
CEMI Chembio Diagnostics	0.00	N/A	N/A	N/A
ELYM Eliem Therapeutics	0.00	N/A	N/A	N/A
NBRV Nabriva Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest CEMI, ELYM, ATNM, and NBRV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
6/24/2025	ATNM Actinium Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATNM Actinium Pharmaceuticals	N/A	N/A	N/A	N/A	$1.31 per share	N/A
CEMI Chembio Diagnostics	$48.34M	0.35	N/A	N/A	$0.48 per share	0.95
ELYM Eliem Therapeutics	N/A	N/A	N/A	N/A	$3.90 per share	N/A
NBRV Nabriva Therapeutics	$35.59M	0.00	N/A	N/A	$0.10 per share	0.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATNM Actinium Pharmaceuticals	-$48.82M	-$1.31	N/A	N/A	N/A	N/A	-100.85%	-47.89%	N/A
CEMI Chembio Diagnostics	-$23.29M	-$1.20	N/A	∞	N/A	-47.03%	-113.57%	-38.22%	N/A
ELYM Eliem Therapeutics	-$35.12M	-$0.53	N/A	∞	N/A	N/A	-47.03%	-45.97%	N/A
NBRV Nabriva Therapeutics	-$57.19M	-$19.20	N/A	N/A	N/A	-148.11%	-365.53%	-135.81%	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATNM Actinium Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CEMI Chembio Diagnostics	N/A	N/A	N/A	N/A	N/A
ELYM Eliem Therapeutics	N/A	N/A	N/A	N/A	N/A
NBRV Nabriva Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATNM Actinium Pharmaceuticals	N/A	10.25	10.25
CEMI Chembio Diagnostics	N/A	1.23	1.04
ELYM Eliem Therapeutics	N/A	60.41	60.41
NBRV Nabriva Therapeutics	0.12	0.85	0.52

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATNM Actinium Pharmaceuticals	27.50%
CEMI Chembio Diagnostics	8.65%
ELYM Eliem Therapeutics	69.76%
NBRV Nabriva Therapeutics	0.27%

Insider Ownership

Company	Insider Ownership
ATNM Actinium Pharmaceuticals	6.00%
CEMI Chembio Diagnostics	3.30%
ELYM Eliem Therapeutics	4.70%
NBRV Nabriva Therapeutics	1.63%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATNM Actinium Pharmaceuticals	30	31.20 million	29.32 million	Optionable
CEMI Chembio Diagnostics	337	36.73 million	35.51 million	Not Optionable
ELYM Eliem Therapeutics	9	29.75 million	28.35 million	Not Optionable
NBRV Nabriva Therapeutics	70	32.02 million	31.49 million	Not Optionable

CEMI, ELYM, ATNM, and NBRV Headlines

Recent News About These Companies

Nabriva Therapeutics plc (NBRVF)

October 19, 2024 | finance.yahoo.com

Meitheal gains rights to Contempo

July 20, 2024 | thepharmaletter.comT

Meitheal gains rights to CONTEPO from Nabriva in North America

July 19, 2024 | pharmaceutical-technology.comP

Nabriva Therapeutics PLC NBRVF

April 13, 2024 | morningstar.comM

Nabriva Therapeutics files patent for a dosing regimen for fosfomycin treatment

December 22, 2023 | pharmaceutical-technology.comP

Arbutus Biopharma Corporation: Arbutus Appoints Two New Executives

July 11, 2023 | finanznachrichten.de

NBRV - Nabriva Therapeutics plc

May 26, 2023 | finance.yahoo.com

Bacterial Pneumonia Therapeutics Market Updated Report by Competitor Strategics till 2029

February 28, 2023 | marketwatch.com

NBRV Nabriva Therapeutics plc

February 25, 2023 | seekingalpha.com

Nabriva Therapeutics Provides Corporate Update

January 6, 2023 | finance.yahoo.com

Nabriva Therapeutics Shares Rise 11% After Positive Xenleta Trial Data

November 28, 2022 | marketwatch.com

Nabriva Adds 9% On Positive Results From Study Of Xenleta In Cystic Fibrosis

November 28, 2022 | markets.businessinsider.com

Nabriva Announces Positive Results From Phase 1 Trial Of Lefamulin In Cystic Fibrosis; Stock Up

November 28, 2022 | markets.businessinsider.com

Nabriva stock up after firm's antibiotic shows promise as a potential cystic fibrosis treatment

November 28, 2022 | bizjournals.com

Nabriva gains after announcing Phase 1 data for cystic fibrosis candidate

November 28, 2022 | seekingalpha.com

Nabriva Therapeutics Announces Positive Topline Results from Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis

November 28, 2022 | finance.yahoo.com

Nabriva's stock is up after sharing antibiotic news

November 28, 2022 | finance.yahoo.com

Nabriva's antibiotic shows promise as a potential cystic fibrosis treatment

November 28, 2022 | finance.yahoo.com

Nabriva Therapeutics describes new 12-epi-mutilin compounds to treat bacterial infections

November 10, 2022 | bioworld.comB

Montgomery County biopharmaceutical firm reducing workforce by 40%

November 10, 2022 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CEMI, ELYM, ATNM, and NBRV Company Descriptions

Actinium Pharmaceuticals NYSE:ATNM

$1.74 +0.03 (+1.75%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.74 0.00 (-0.29%)

As of 08/22/2025 07:33 PM Eastern

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.

Chembio Diagnostics NASDAQ:CEMI

Chembio Diagnostics, Inc. engages in the developing, manufacturing, marketing, and licensing of rapid medical tests. It offers rapid point-of-care tests for infectious, tropical and fever, and respiratory diseases, handheld analyzers, and veterinary products. The firm distributes its products to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. The company was founded in 1985 and is headquartered in Medford, NY.

Eliem Therapeutics NASDAQ:ELYM

$2.38 +0.19 (+8.68%)

As of 08/22/2025

Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.

Nabriva Therapeutics NASDAQ:NBRV

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time